Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

21 results
Display

Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Kim JH, Ahn B, Hong SM, Jung HY, Kim DH, Choi KD, Ahn JY, Lee JH, Na HK, Kim JH, Kim YH, Kim HR, Lee HJ, Kim SB, Park SR

Purpose This study aimed to evaluate the real-world efficacy of immune checkpoint inhibitors (ICIs), and to identify clinicolaboratory factors to predict treatment outcomes in patients with advanced esophageal squamous cell...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Drug-Induced Sarcoidosis-Like Reaction in Lung Cancer Patient Treated with Nivolumab and Ipilimumab: A Case Report and Literature Review

Kim SH, Lee SG, Kim JY, Ju HJ, Kim GM, Lee JH

  • KMID: 2527682
  • Korean J Dermatol.
  • 2022 Mar;60(3):182-185.
Immune checkpoint inhibitor (ICI), including programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4 inhibitors, has emerged as a pillar in the management of advanced malignancies. A drug-induced sarcoidosis-like...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Impact of Prognostic Nutrition Index for Advanced Gastric Cancer Patients with Peritoneal Metastases Treated Nivolumab Monotherapy

Lee J, Choi SH, Baek JH, Baek DW, Kim JG, Kang BW

Although nivolumab shows survival benefits for patients with advanced gastric cancer (AGC), predictive biomarkers for nivolumab treatment in AGC remain unclear, especially in the case of peritoneal metastases. This study...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Usage Patterns and Incidence of Thyroid-related Adverse Events in Patients Treated with PD-1 Inhibitors

Hwang S, Kim H, Chung S, Min M, Suh DC

Objective: PD-1 inhibitors have demonstrated improved health outcomes in cancer patients. PD-1 inhibitors are well-tolerated and associated with immune-related adverse events. The objectives of this study are to analyze use...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report

Han JE, Cho HJ, Kim SS, Cheong JY

The current Food and Drug Administration-approved systemic treatments for advanced hepatocellular carcinoma (HCC) include multikinase inhibitors (tyrosine kinase inhibitor [TKI]) and immune checkpoint inhibitors (ICIs). Among ICIs, nivolumab is used...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cutaneous Adverse Events of Anti-Programmed Cell Death Receptor-1 Antibody: Two Case Reports and a Literature Review

Lim JS, Kim HH, Kwon ES, Myung KB, Cheong SH

  • KMID: 2520804
  • Korean J Dermatol.
  • 2021 Sep;59(8):644-648.
The introduction of immune checkpoint inhibitors, including anti-programmed cell death receptor-1 antibodies (anti-PD-1 Ab), such as nivolumab and pembrolizumab, represents a major breakthrough in cancer therapy. The PD-1 pathway inhibits...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report

Cho HJ, Kim WR, Kim JH, Kim DH, Kim DJ, Kang H

With the advent of checkpoint inhibitors, it has opened up opportunities for numerous cancer patients. However, as is the case with every treatment, complications need to be weighed. Gastrointestinal adverse...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review

Kim KH, Sim WY, Lew BL

Nivolumab (anti-PD-1) currently used in many cancers. With the usage of nivolumab increased, many cutaneous side effects were reported including maculopapular rash, lichenoid reactions, vitiligo, bullous disorders, psoriasis exacerbation, and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Analysis of the Dermatologic Side Effects and the Factors Affecting the Efficacy of Immune Checkpoint Inhibitor in Melanoma: A Single-Center, Retrospective Study

Yoon D, Oh SJ, Kim HJ, Park JH, Lee JH, Lee DY, Lee JH

  • KMID: 2516137
  • Korean J Dermatol.
  • 2021 May;59(4):251-258.
Background: Programmed death 1 inhibitors enhance pre-existing immune responses by directly blocking anti-programmed cell death receptor-1. They have been widely used these days, but little is known about the dermatologic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment

Lee CH, Lee YB, Kim MA, Jang H, Oh H, Kim SW, Cho EJ, Lee KH, Lee JH, Yu SJ, Yoon JH, Kim TY, Kim YJ

Background/Aims: Several treatment options are currently available for patients with hepatocellular carcinoma (HCC) failing previous sorafenib treatment. We aimed to compare the effectiveness of regorafenib and nivolumab in these patients. Methods:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study

Hur JY, Yoon SE, Kim SJ, Kim WS

Background Immune checkpoint inhibitors have demonstrated efficacy in the treatment of classical Hodgkin’s lymphoma (cHL). We analyzed the efficacy and safety of pembrolizumab or nivolumab in patients with pretreated cHL. Methods...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of Efficacy and Safety of Nivolumab and Pembrolizumab in Elderly Cancer Patients

Kim HS, Jeong H, Shim MK

Background: Nivolumab and pembrolizumab are antagonists of the programmed death-ligand 1 (PD-L1) receptor that function as immuno-oncological agents. This study aimed to evaluate the safety and efficacy of nivolumab and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure

Kim J, Chang JW, Park JY

Over the past decade, standard first-line systemic treatment of advanced hepatocellular carcinoma (HCC) has been based on sorafenib, a multi-kinase inhibitor. Regorafenib, another tyrosine kinase inhibitor, is the only second-line...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Lichen Planus Developed During the Treatment with Nivolumab in a Patient with Lung Cancer: A Case Report and Literature Review

Park E, Koo T, Jo M, Yoo J, Park J

  • KMID: 2465922
  • Korean J Dermatol.
  • 2019 Nov;57(9):551-555.
Nivolumab is a fully-humanized IgG4 monoclonal antibody that competitively binds to the programmed cell death receptor-1 protein (an immune check-point molecule) present on activated T cells. Nivolumab is approved for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Nivolumab-induced Cutaneous Toxicity

Choi W, Myung KB, Hahn HJ, Cheong SH

  • KMID: 2457689
  • Korean J Dermatol.
  • 2019 Aug;57(7):383-386.
Nivolumab is anti-programmed death 1 (PD1) receptor antibody, which can be used in the treatment of metastatic squamous cell cancer. By blocking the PD1 receptors on T cells, it enhances...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Lichenoid Drug Eruption Developed in Melanoma Patient Treated with Nivolumab

Hong KR, Kwon R, Kim JE, Park YL, Lee SH

  • KMID: 2454380
  • Korean J Dermatol.
  • 2019 Jul;57(6):343-345.
No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy

Lee YJ, Kim HT, Won CH, Chang SE, Lee MW, Choi JH, Lee WJ

BACKGROUND: Anti-programmed cell death-1 (PD-1) immunotherapy using antibodies such as nivolumab or pembrolizumab has shown promise for treating various types of cancer. In this study, we reviewed the frequency and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Achieving Partial Remission with the Combination of Sorafenib and Nivolumab in a Patient with Hepatocellular Carcinoma Showing Disease Progression after Nivolumab Therapy

Hwang SY, Lee SM, Im JW, Jeon KJ, Choi CW, Kim KS, Jeon W

Sorafenib is a well-known approved systemic therapeutic agent used in patients with advanced hepatocellular carcinoma (HCC). Regorafenib and nivolumab are approved as second-line therapeutic drugs in patients showing disease progression...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pneumocystis Pneumonia Developing during Treatment of Recurrent Renal Cell Cancer with Nivolumab

Kim HR, Keam B, Park YS, Kim M, Kim TM, Kim DW, Heo DS

Nivolumab is an immune checkpoint inhibitor approved for the treatment of metastatic cancers. Here, we report the case of a 65-year-old male with recurrent renal cell carcinoma. After six cycles...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of Nivolumab Use and Factors related to Treatment Outcomes in a Cancer Center of a Top Tier General Hospital

Eoum G, Cho Y, Rhie SJ

BACKGROUND: We strived to evaluate the status of nivolumab use and associated factors on the clinical efficacy of the drug. METHODS: The study was retrospectively conducted in patients who had been...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr